TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05701982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Every Step Counts-Tai Chi
Description: The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT05859607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: conventional laparoscopic cholecystectomy with calculation of difficulty scorings

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: conventional laparoscopic cholecystectomy with calculation of difficulty scorings

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: conventional laparoscopic cholecystectomy with calculation of difficulty scorings
Study: NCT06346847

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic
Description: 1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
Study: NCT06306469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation practice
Description: physical and breathing exercises
Study: NCT05634278

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative mindfulness
Description: A seven-minute, audio-guided, mindfulness meditation practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative mindfulness
Description: A seven-minute, audio-guided, mindfulness meditation practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative mindfulness
Description: A seven-minute, audio-guided, mindfulness meditation practice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mind wandering
Description: A timed, seven-minute mind wandering period during which participants are instructed: For the next 7 minutes, allow your mind to wander.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind wandering
Description: A timed, seven-minute mind wandering period during which participants are instructed: For the next 7 minutes, allow your mind to wander.
Study: NCT05926778

Intervention type: OTHER
Intervention: Liver allograft fibrosis
Description: Observational studies without intervention
Study: NCT05639608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCALING
Description: SCALING WILL BE DONE AT BASELINE IN TEST GROUP.
Study: NCT04990362

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate oil, Mediterranean Diet
Description: Dietary Supplement: Pomegranate oil in a glass bottle of 0.15ml per day +Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Dietary Supplement: Mediterranean dietary protocol
Study: NCT04622553

Intervention type: DRUG
Group type: OTHER
Intervention: Mexiletine
Description: Patients will be enrolled sequentially into 2 cohorts.~Cohort 1 - (patients aged 12 to \< 18 years):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2- (patients aged 6 to \< 12 years,):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Enrolment for Cohort 2 will begin after initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, of patients in Cohort 1
Study: NCT05715177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cura Kinesio-taping
Description: Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length will be applied on origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo kinesio-taping
Description: Placebo kinesiotaping
Study: NCT06399562

Intervention type: DIAGNOSTIC_TEST
Intervention: carbon-13 urea breath test (13C-UBT)
Description: The H. pylori infection was detected by carbon-13 urea breath test (13C-UBT), a delta over baseline (DOB) of ≥4.0 was considered positive for H. pylori, and a DOB\<4.0 was considered negative.

Intervention type: DIAGNOSTIC_TEST
Intervention: carbon-13 urea breath test (13C-UBT)
Description: The H. pylori infection was detected by carbon-13 urea breath test (13C-UBT), a delta over baseline (DOB) of ≥4.0 was considered positive for H. pylori, and a DOB\<4.0 was considered negative.

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The related factors of H. pylori infection were investigated by questionnaire survey. The physical examination population participated in the questionnaires of the physical examination center, which included basic demographic characteristics and living habits, and filled out the questionnaires on the use of serving chopsticks at the same time. In the community, members of each eligible family were asked to complete a questionnaire including the details such family general information, basic information of every family member, personal living habits, past medical history, and so on.

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The related factors of H. pylori infection were investigated by questionnaire survey. The physical examination population participated in the questionnaires of the physical examination center, which included basic demographic characteristics and living habits, and filled out the questionnaires on the use of serving chopsticks at the same time. In the community, members of each eligible family were asked to complete a questionnaire including the details such family general information, basic information of every family member, personal living habits, past medical history, and so on.
Study: NCT04255758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle Ergometer Exercise
Description: 25 minutes, 70% VO2max steady state cycle ergometry exercise
Study: NCT05716295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDK-703
Description: MDK-703 will be administered as specified under Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDK-703
Description: MDK-703 will be administered as specified under Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor, Immune
Description: Checkpoint inhibitor will be administered as specified under Arm description.
Study: NCT05662189

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-exendin-4
Description: 68Ga-exendin4 PET-CT scan

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-exendin-4
Description: 68Ga-exendin4 PET-CT scan

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-exendin-4
Description: 68Ga-exendin4 PET-CT scan

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-exendin-4
Description: 68Ga-exendin4 PET-CT scan

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-exendin-4
Description: 68Ga-exendin4 PET-CT scan

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-exendin-4
Description: 68Ga-exendin4 PET-CT scan

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-exendin-4
Description: 68Ga-exendin4 PET-CT scan

Intervention type: OTHER
Group type: OTHER
Intervention: mixed meal test
Description: before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

Intervention type: OTHER
Group type: OTHER
Intervention: mixed meal test
Description: before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

Intervention type: OTHER
Group type: OTHER
Intervention: mixed meal test
Description: before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

Intervention type: OTHER
Group type: OTHER
Intervention: mixed meal test
Description: before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

Intervention type: OTHER
Group type: OTHER
Intervention: mixed meal test
Description: before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

Intervention type: OTHER
Group type: OTHER
Intervention: mixed meal test
Description: before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves

Intervention type: OTHER
Group type: OTHER
Intervention: mixed meal test
Description: before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves
Study: NCT04827979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~* calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~* cPRA \>98% (with \>5 years of waiting time) awaiting living donor transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~* calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~* cPRA \>98% (with \>5 years of waiting time) awaiting living donor transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
Study: NCT05897242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: Use ACT on Vaping smartphone app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Message
Description: Receive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06523959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation
Study: NCT04853823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-APB
Description: PDC-APB Intra-muscular Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT05074134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TNP-2092
Description: Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).
Study: NCT06251141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gum Health gel
Description: Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket with normal saline, and filling the socket with the Gum Health gel

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gel foam
Description: Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket
Study: NCT05468216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MovIn-Lessons group
Description: The MovIn-Lessons intervention will consist of infusing PA in math, English and natural sciences lessons in primary education. The movement will be integrated in the learning activities for at least 20 minutes per session, at different physical intensities.
Study: NCT05717491

Intervention type: OTHER
Intervention: Biological analysis, Physical examination and Questionnaires
Description: Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.

Intervention type: OTHER
Intervention: Physical examination and Questionnaires
Description: In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
Study: NCT06118580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (Ethanol)
Description: 95% Ethanol diluted in Grape-flavored drink

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Grape-flavored drink
Study: NCT05187429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML [Opdivo]
Description: Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML [Opdivo]
Description: Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
Study: NCT04722107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2/8-hCYP4V2
Description: rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
Study: NCT05447143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale
Description: Evaluation for severity of fatigue

Intervention type: OTHER
Group type: OTHER
Intervention: Fatigue Severity Scale
Description: Evaluation for severity of fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale
Description: Evaluation for severity of fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berg Balance Test
Description: Evaluation of balance

Intervention type: OTHER
Group type: OTHER
Intervention: Berg Balance Test
Description: Evaluation of balance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berg Balance Test
Description: Evaluation of balance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time up and go- 25 steps walking test
Description: Evaluation for walking

Intervention type: OTHER
Group type: OTHER
Intervention: Time up and go- 25 steps walking test
Description: Evaluation for walking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time up and go- 25 steps walking test
Description: Evaluation for walking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Quality of Life
Description: Evaluation of quality of life

Intervention type: OTHER
Group type: OTHER
Intervention: Multiple Sclerosis Quality of Life
Description: Evaluation of quality of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Quality of Life
Description: Evaluation of quality of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief International Cognitive Assessment for MS (BICAMS)
Description: Evaluation of cognitive functions

Intervention type: OTHER
Group type: OTHER
Intervention: Brief International Cognitive Assessment for MS (BICAMS)
Description: Evaluation of cognitive functions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief International Cognitive Assessment for MS (BICAMS)
Description: Evaluation of cognitive functions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beck Depression and Anxiety Scale
Description: Evaluation of depression and anxiety

Intervention type: OTHER
Group type: OTHER
Intervention: Beck Depression and Anxiety Scale
Description: Evaluation of depression and anxiety

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beck Depression and Anxiety Scale
Description: Evaluation of depression and anxiety
Study: NCT06393725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asynchronous Remote Lifestyle Intervention
Description: A 1 year lifestyle intervention based on the Diabetes Prevention Program to be delivered asynchronously via a private Facebook group led by a professional weight loss counselor. In the subsequent year, a Peer-Led Maintenance Phase will occur in which a participant volunteer will lead the group after receiving a brief training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Synchronous Remote Lifestyle Intervention
Description: A 1 year lifestyle intervention based on the Diabetes Prevention Program to be delivered synchronously via weekly videoconference group meetings led by a professional weight loss counselor. In the subsequent year, a Peer-Led Maintenance Phase will occur in which a participant volunteer will lead the group after receiving a brief training.
Study: NCT06477744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_Low Dose
Description: 1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -Low Dose : 7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_High Dose
Description: 1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -High Dose : 1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side.
Study: NCT05488769

Intervention type: DEVICE
Intervention: Clareon Vivity extended depth of focus (EDOF) intraocular lens
Description: Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
Study: NCT05287490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FormaV and VTone
Description: Eligible subjects will receive 3 treatments(every 2 weeks) with the FormaV and VTone Applicators according to the study protocol.
Study: NCT03175887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
Study: NCT05865912

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mindfulness training + real tDCS
Description: The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently.~TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start (ramping up) and end (ramping down) of the 20 minute period.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness training + sham tDCS
Description: Mindfulness training + sham tDCS